GE HealthCare announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S. based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Financial terms were not disclosed. Based on this agreement, GE HealthCare will take on global rights for [68Ga]FAPI-46 and outside-U.S. rights for [18F]FAPI-74, originally developed at Heidelberg University in Germany, and both ([68Ga]FAPI-46 (NCT05262855)2 and [18F]FAPI-74 (NCT05641896)3) currently in Phase II clinical trials in the U.S.. SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S.

To read more please visit:

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Source: GE HealthCare